Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Donald Wender (NPI 1861463275)

Field	Value
Entity Type	Individual
Organization	Donald Wender
Address	230 Nebraska St
City	Sioux City
State	IA
ZIP	51101
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	February 1, 2006

Payer Source	Total Paid
Medicare	$2.6M
Medicaid	$0

Key Findings

Revenue scale and payer mix: This provider reports $2.6M in lifetime Medicare revenue and has no Medicaid billing on file, making the practice effectively single-payer (Medicare) in the available dataset. The absence of any Medicaid claims means Medicaid-driven service-line or network participation analysis is not possible from these records.

High concentration in immuno-oncology agents: Three drug J‑codes drive the bulk of Medicare revenue — J9271 (23K claims, $989K; 38.4%), J9299 (29.8K claims, $684.5K; 26.6%), and J9144 (8.1K claims, $307.8K; 12.0%) — which together account for 76.9% of this provider's total Medicare revenue. This concentration indicates the practice is heavily oriented toward high-cost oncology infusions, particularly checkpoint inhibitors and monoclonal antibody therapies.

Operational profile and service mix: Beyond the J‑codes, the presence of chemotherapy administration codes (96413, 96417, 96365, 96375) plus supportive drugs such as J2506 (pegfilgrastim) and J0897 (denosumab) shows an integrated outpatient oncology infusion operation that delivers both immuno-oncology agents and standard chemotherapy with associated supportive care. The mix of infusion, administration add-ons, and supportive injections is consistent with a clinic that performs frequent outpatient infusions rather than primarily consultative or surgical oncology care.

Competitive standing on top oncology drugs: For the two largest revenue codes, the provider ranks in the upper national quartile but not at the top — J9271 ranks #277 of 1841 providers (85th percentile; typical, unremarkable volume) and J9299 ranks #79 of 505 providers (85th percentile; typical, unremarkable volume). J9144 is more middle-of-market at #308 of 615 (49th percentile; typical, unremarkable volume), indicating solid but not dominant national positioning for these specific biologic therapies.

High outpatient visit and lab throughput relative to national peers: Several office/outpatient E/M and common lab codes are at very high national percentiles — 99214 (95th percentile; notably above typical), 99213 (95th percentile; notably above typical), 99212 (97th percentile; notably above typical), 80053 (97th percentile), and 85025 (97th percentile). These elevated percentiles suggest the provider has above-typical visit volumes and frequent in-office testing relative to the broader national cohort of Medicare-billing clinicians.

Selective use of biosimilars and other agents: The provider reports use of the rituximab biosimilar Q5115 (1.8K claims, $64.4K) but ranks low nationally for that code (#63 of 79; 19th percentile; typical, unremarkable volume), indicating biosimilar usage exists but is not a major driver of revenue compared with the dominant checkpoint inhibitors. This pattern points to a treatment mix focused more on PD‑1/PD‑L1 agents than on B‑cell targeted therapies.

Tenure and continuity: The NPI was enumerated on 2006-02-01 (~20 years ago), indicating long-standing Medicare enrollment and likely sustained practice operations over time, which supports interpreting the current billing pattern as the product of an established outpatient oncology service rather than a short-term or recently opened clinic.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

77 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	23,000	$40	$989K
J9299	Injection, nivolumab, 1 mg	29,760	$20	$684.5K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	8,100	$40	$307.8K
J0897	Injection, denosumab, 1 mg	7,200	$20	$129.6K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	2,680	$40	$96.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	740	$90	$64.7K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	1,790	$40	$64.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	530	$90	$49.3K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	380	$90	$34.6K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	540	$60	$32.9K

Showing 1–10 of 77

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 77 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

Donald Wender — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

77 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	6	30	17,200	$40	$902.3K
J9299	3	10	18,700	$20	$527.6K
J9144	6	10	9,900	$40	$476.8K
J1569	6	10	2,680	$40	$133.6K
J0897	27	190	1,920	$20	$74.1K
Q5115	5	10	1,790	$30	$71.4K
J2506	9	20	440	$80	$38.9K
96413	10	80	210	$90	$24K
99214	209	4,690	100	$70	$14.4K
99233	238	910	60	$90	$10.5K

Showing 1–10 of 77

Related Providers

Other providers that share a Tax Identification Number (TIN) with Donald Wender, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mary Washington Hospital Inc.	VA	General Acute Care Hospital	$0	$80.1M
Northwest Iowa Hospital Corporation	IA	General Acute Care Hospital	$0	$22.8M
Thomas Buroker	IA	Medical Oncology Physician	$9.4M	$0
Kyle Alliman	IA	Ophthalmology Physician	$8.7M	$0
Alex Kartvelishvili	IA	Ophthalmology Physician	$8.1M	$0
Northwest Iowa Hospital Corporation	IA	Emergency Medical Services (Emergency Medicine) Physician	$0	$7.9M
Paul Boeke	IA	Ophthalmology Physician	$7.1M	$0
Austin Strohbehn	IA	Retina Specialist (Ophthalmology) Physician	$5.8M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Robert Behrens	IA	Medical Oncology Physician	$5.2M	$0

Nearby Providers

Other providers in the same ZIP code as Donald Wender, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Jackson Recovery Centers, Inc.	IA	Substance Abuse Rehabilitation Facility	$0	$28.5M
Siouxland Mental Health Services, Inc.	IA	Community/Behavioral Health Agency	$0	$25.7M
City Of Sioux City Accounting Division	IA	Ambulance	$520.5K	$19.2M
Marian Health Center-smhc	IA	General Acute Care Hospital	$0	$15.5M
Family Health Care Of Siouxland Plc	IA	Family Medicine Physician	$0	$11.1M
Family Wellness Associates, Inc.	IA	Community/Behavioral Health Agency	$0	$4M
Woodbury Emergency Group, PC	IA	Emergency Medicine Physician	$0	$3M
Building Bridges Counseling & Associates Inc	IA	Community/Behavioral Health Agency	$0	$2.5M
Mercy Medical Services	IA	Internal Medicine Physician	$0	$2M
Counseling And Support Services Inc	IA	Social Worker	$0	$1.8M

Donald Wender — Billing Profile & Reimbursement Data

Sign up for Donald Wender — Billing Profile & Reimbursement Data policy alerts

Donald Wender — Billing Profile & Reimbursement Data

Sign up for Donald Wender — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References